Evaluation of Soluble ST2 in Patients Receiving Primary PCI With ST-elevation Myocardial Infarction
NCT ID: NCT02830217
Last Updated: 2019-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2015-12-31
2018-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset
NCT04962178
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
NCT03406819
DCB Under the Guidance of OCT in STEMI
NCT05680051
The Thrombus Aspiration During PCI After Thrombolysis in STEMI
NCT06654453
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
NCT03406832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
STEMI patients having primary PCI
Patients with STEMI receiving primary PCI in Wuhan Aisa Heart Hospital are included in this study. All patients are the first time to have STEMI, and primary PCIs are performed according to 2013 ACCF/AHA guideline for the management of STEMI. Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases are excluded from this study.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
25 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuhan Asia Heart Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xuan Zheng
vice director of laboratory of molecular cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xuan Zheng, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Wuhan Asia Heart Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016LMC-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.